The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

American Journal of Cardiology

Volumn 93, Issue 2, 2004, Pages 136-141

  Girman, Cynthia J ^a   Rhodes, Thomas ^b   Mercuri, Michele ^b   Pyörälä, Kalevi ^b   Kjekshus, John ^b   Pedersen, Terje R ^b   Beere, Polly A ^b   Gotto, Antonio M ^b   Clearfield, Michael ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; AIR FORCE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; SURVIVAL; TREATMENT OUTCOME; UNITED STATES;

EID: 0346962890     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.09.028     Document Type: Article

References (19)

1. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
2. Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. Am J Cardiol. 71:1993;393-400.
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
4. Downs J.R., Beere P.A., Whitney E., Clearfield M., Weis S., Rochen J., Stein E.A., Shapiro D.R., Langendorfer A., Gotto A.M. Design and rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS). Am J Cardiol. 80:1997;287-293.
5. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of AFCAPS/TexCAPS Air Force/Texas Coronary Atherosclerosis Prevention Study . JAMA. 279:1998;1615-1622.
6. Clearfield M., Whitney E., Weis S., Downs J.R., Shapiro D.R., Stein E.A., Watson D.J., Langendorfer A., Beere P.A., Stamler J., Gotto A.M. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) baseline characteristics and comparison with USA population . J Cardiovasc Risk. 7:2000;125-133.
7. Assmann G., Cullen P., Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Münster (PROCAM) Study. Circulation. 105:2002;310-315.
8. Alexander C.M., Landsman P.B., Teutsch S.M., Haffner S.M. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 52:2003;1210-1214.
9. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults-findings from the Third National Health and Nutrition Examination Survey. JAMA. 287:2002;356-359.
10. Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., Taskinen M.R., Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 24:2001;683-689.
11. Pyörälä M., Miettinen H., Halonen P., Laakso M., Pyörälä K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men. The 22-year follow-up results of the Helsinki Policeman Study. Arterioscler Thromb Vasc Biol. 20:2000;538-544.
12. Klein B.E.K., Klein R., Lee K.E. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care. 25:2002;1790-1794.
13. McNeill A.M., Girman C.J., Rosamond W., Ballantyne C.M. A new definition of the metabolic syndrome predicts incident coronary heart disease and ischemic stroke (abstr). Circulation. 106:(suppl 19):2002;II-765.
14. Resnick H.E., Jones K., Ruotolo G., Jain A.K., Henderson J., Lu W., Howard B.V. Insulin resistance, the metabolic syndrome and risk of incident cardiovascular diseases in nondiabetic American Indians. The Strong Heart Study. Diabetes Care. 26:2003;861-867.
15. Hanson R.L., Imperatore G., Bennett P.H., Knowler W.C. Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes. 51:2002;3120-3127.
16. Wilson P.W.F., D'Agostino R.B. Sr, Parise H., Meigs J.B. The metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus (abstr). Diabetes Care. 51:(suppl 2):2002;A242.
17. Bonora E., Kiechl S., Willeit J., Oberhollenzer F., Egger G., Bonadonna R.C., Muggeo M. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome prospective data from the Bruneck Study . Diabetes Care. 26:2003;1251-1257.
18. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., Salonen J.T. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 288:2002;2709-2716.
19. Ballantyne C.M., Olsson A.G., Cook T.J., Mercuri M.F., Pedersen T.R., Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglycerides on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 104:2001;3046-3051.